Robert D. Schreiber

Robert D. Schreiber, PhD, is Alumni Endowed Professor of Pathology and Immunology and Director of the Center for Human Immunology and Immunotherapy Programs at Washington University School of Medicine. He is one of the most influential theorists in cancer immunology. Dr. Schreiber developed the cancer immunoediting theory, a foundational framework explaining how the immune system shapes cancer development through three phases: Elimination, Equilibrium, and Escape. His landmark 2001 Nature paper (PMID 11357140, 3,000+ citations) and comprehensive 2002 Nature review (PMID 12479812, 8,000+ citations) established immunoediting as a central concept in cancer biology, providing the theoretical basis for understanding why checkpoint inhibitors succeed or fail. Dr. Schreiber's research elucidated how tumors evade immune destruction and identified interferon-gamma signaling as critical for immune surveillance. His work on neoantigen discovery demonstrated that T cells recognize tumor-specific mutated peptides, providing mechanistic insight into why checkpoint blockade works. His studies on tumor immunogenicity and immune escape mechanisms directly informed the clinical development of immune checkpoint inhibitors. Elected to the National Academy of Sciences (2003) and National Academy of Medicine (2018), Dr. Schreiber received the William B. Coley Award (2007), the AACR-CRI Lloyd J. Old Award (2010), the AAI Lifetime Achievement Award, and multiple other prestigious honors. His cancer immunoediting theory has fundamentally shaped our understanding of tumor immunity and checkpoint therapy.

Robert D. Schreiber哲学博士现任华盛顿大学医学院Alumni冠名病理学与免疫学教授以及人类免疫学和免疫治疗项目中心主任。他是癌症免疫学领域最具影响力的理论家之一。 Schreiber博士发展了癌症免疫编辑理论，这是一个解释免疫系统如何通过三个阶段塑造癌症发展的基础框架：消除、平衡和逃逸。他2001年Nature里程碑论文(PMID 11357140, 引用3,000+次)和2002年综合Nature综述(PMID 12479812, 引用8,000+次)确立了免疫编辑作为癌症生物学的核心概念，为理解检查点抑制剂为何成功或失败提供了理论基础。 Schreiber博士的研究阐明了肿瘤如何逃避免疫破坏，并确定了干扰素-γ信号对免疫监视的关键作用。他在新抗原发现方面的工作证明T细胞识别肿瘤特异性突变肽，为理解检查点阻断为何有效提供了机制性见解。他关于肿瘤免疫原性和免疫逃逸机制的研究直接影响了免疫检查点抑制剂的临床开发。 Schreiber博士2003年当选美国国家科学院院士、2018年当选美国国家医学院院士，获William B. Coley奖(2007)、AACR-CRI Lloyd J. Old奖(2010)、AAI终身成就奖以及多项其他殊荣。他的癌症免疫编辑理论从根本上塑造了我们对肿瘤免疫和检查点治疗的理解。